<DOC>
	<DOCNO>NCT01866319</DOCNO>
	<brief_summary>This study evaluate safety efficacy 2 different dose schedule pembrolizumab ( MK-3475 ) , every 2 week ( Q2W ) every 3 week ( Q3W ) , compare 2 schedule treatment ipilimumab ipilimumab-na√Øve participant unresectable metastatic melanoma . Participants assign treatment pembrolizumab could receive 2 year treatment ; participant stop treatment 2 year later experience progression , eligible second course treatment 1 additional year . With Amendment 05 , Second Course participant treat fix dose pembrolizumab 200 mg Q3W .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Two Different Dosing Schedules Pembrolizumab ( MK-3475 ) Compared Ipilimumab Participants With Advanced Melanoma ( MK-3475-006/KEYNOTE-006 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Histologicallyconfirmed diagnosis unresectable Stage III metastatic melanoma amenable local therapy ( exclude uveal ocular melanoma ) At least one measurable lesion No prior systemic treatment ( exclude adjuvant neoadjuvant therapy ) melanoma ( first line ) one prior systemic treatment ( exclude adjuvant neoadjuvant therapy ) melanoma ( second line ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Archived tissue sample new biopsy sample Female participant childbearing potential must agree use effective contraception Visit 1 120 day last dose study drug ; male participant must agree use adequate method contraception start first dose study drug 120 day last dose study drug Exclusion criterion : Prior treatment ipilimumab anticytotoxic TLymphocyte Antigen 4 ( CTLA4 ) agent antiprogrammed cell death ( PD1 PDL2 ) agent Chemotherapy , radioactive , biological cancer therapy within four week prior first dose study drug , recover adverse event cause cancer therapeutic administer four week earlier Currently participate participate study investigational agent use investigational device within 30 day first dose study drug Expected require form systemic localize antineoplastic therapy study On systemic steroid therapy within one week plan date first dose randomize treatment form immunosuppressive medication History malignancy ( disease treatment study ) within 5 year prior first study drug administration , exclude adequately treat Stage 1 Stage 2 basal/squamous cell carcinoma skin , carcinoma situ cervix breast , situ cancer . Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis ; participant previously treat brain metastasis eligible Severe hypersensitivity reaction treatment another monoclonal antibody Active autoimmune disease document history autoimmune disease syndrome require systemic steroid immunosuppressive agent Active infection require systemic therapy Known history Human Immunodeficiency Virus ( HIV ) Known history positive Hepatitis B C Known psychiatric substance abuse disorder Regular user ( include recreational use ) illicit drug recent history ( within last year ) substance abuse ( include alcohol ) Pregnant breastfeeding , expect conceive , father child within project duration study Received live vaccine within 30 day prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PD-1</keyword>
	<keyword>PD1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL1</keyword>
</DOC>